Refine by
Therapeutic Area Drug Articles & Analysis
74 news found
Due to their unique specificity and high activity, enzymes demonstrate significant potential in therapeutic drug development. However, their broader application is hindered by several limitations, the most significant of which are poor stability, potential immunogenicity and systemic toxicity risks. Considerable attention has been drawn to the use of ...
Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. The assigned DMF number is 041864. This significant achievement underscores Biopharma PEG's robust ...
The topics set for the 2025 edition would highlight small-molecule drug discovery, novel modalities, and translational technologies with a particular focus on targeting protein degradation, RNA therapeutics, and precision drug delivery systems, which are all areas where BOC Sciences has built extensive expertise for years. ...
Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. ...
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s ...
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for ...
This versatility enables the development of advanced solutions for targeted therapies, allowing adaptation of MOFs to specific therapeutic interventions. Strengthening Drug Delivery with Advanced Expertise CD Formulation’s MOF customization service stands out due to its strong foundation in research and technological expertise. ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat ...
Ace Therapeutics is a preclinical contract research provider engaged in ophthalmic diseases. To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of ...
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the different types of quality control (QC) required for iPSCs with a ...
CD Formulation has been dedicated to pharmaceutical advancements, showcasing immense expertise in the development and optimization of micro-reservoir controlled-release drug delivery systems. These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. Transdermal drug delivery systems are very popular ...
However, due to their scarcity and diversity, research in this area has been traditionally challenging, making this development a beacon of hope for patients and researchers worldwide. ...
One of the key areas of focus for CD Formulation is its Novel Drug Delivery System (NDDS) services. ...
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
Follows recent financing round led by Novalis LifeSciences LLC, with investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien joining the board of directors Strategic focus includes customized lipid nanoparticles (cLNPs) mRNA chemistries and process capabilities as enabling technologies driving company excellence etherna (“the Company”), a leading ...
ByeTheRNA
CD BioGlyco, a leader in glycosylation characterization, recently developed a comprehensive glycoproteomics platform to provide its customers worldwide with the characterization of glycosylation in protein drugs. Glycoproteins, such as glycosyltransferases, glycosidases, erythropoietin, and cytokines, make up the majority of biotherapeutic products. Although the drugs themselves are ...
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release. The meetings featuring CTT presentations include the American Society of Clinical ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to the clinic, ...
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ...